FOXA1 and breast cancer: Mechanistically, tamoxifen treatment of breast cancers with wild-type ARID1A results in recruitment of HDAC1 to ARID1A-FOXA1-ER bound enhancers, resulting in decreased ER activity (Figure 1C).